Sandoz US News
Princeton, New Jersey, November 19, 2015 – Sandoz today announced the US market re-introduction of metaxalone tablets, a generic version of SKELAXIN® (distributed by Pfizer Inc)1.
Generic medicines saved the US healthcare system a record USD 254 billion in 2014, according to a new report compiled by the IMS Institute for Healthcare Informatics on behalf of the US Generic Pharmaceutical Association (GPhA).
IMPORTANT INFORMATION ABOUT TEMOZOLOMIDE CAPSULES (GENERIC)
Use our Product Catalog tool to search our database for information regarding a specific Sandoz product in the US.
Visit our multimedia gallery to learn about Sandoz.
Click below for important links.
Our people are our greatest resource. We are always looking for new colleagues to share in our passion and commitment to making the world a healthier place.
Transitioning to civilian service soon? Consider a career with Sandoz, a Novartis company. Learn about our mission, and why you should explore being a part of our team.
Sandoz is a world leader in generic pharmaceuticals, providing access to a wide array of high-quality, affordable medicines. In the US, Sandoz markets more than 200 different generic drugs, including enoxaparin sodium injection, the first generic version of Lovenox®, and Omnitrope®, the groundbreaking follow-on biologic. Our 2,300 US associates are proud to make Sandoz a "healthy decision."
As part of the Novartis group, we believe that superior quality is the key to our long-term success. Our state-of-the-art technologies, decades of experience, and rigorous across-the-board quality standards all contribute to our broad portfolio of premium quality generic medicines.
We use innovation and expertise to go beyond standard generics and develop even the most complex medicines, which add value to patient healthcare – from generic injectables and ophthalmics to biosimilars and respiratory. Driving patient access to cost-effective treatment is how we are shaping the future of healthcare.
Sandoz was the first company to develop and market follow-on versions of highly-complex biopharmaceuticals. Today, we are the undisputed global leader in this segment and have an industry-leading pipeline that will make essential biologics more affordable for all.